Search Results - "Francica, Brian"

Elective Nodal Irradiation Attenuates the Combinatorial Efficacy of Stereotactic Radiation Therapy and Immunotherapy by Marciscano, Ariel E, Ghasemzadeh, Ali, Nirschl, Thomas R, Theodros, Debebe, Kochel, Christina M, Francica, Brian J, Muroyama, Yuki, Anders, Robert A, Sharabi, Andrew B, Velarde, Esteban, Mao, Wendy, Chaudhary, Kunal R, Chaimowitz, Matthew G, Wong, John, Selby, Mark J, Thudium, Kent B, Korman, Alan J, Ulmert, David, Thorek, Daniel L J, DeWeese, Theodore L, Drake, Charles G

“…In the proper context, radiotherapy can promote antitumor immunity. It is unknown if elective nodal irradiation (ENI), a strategy that irradiates…”
Get full text

Stereotactic Radiation Therapy Augments Antigen-Specific PD-1-Mediated Antitumor Immune Responses via Cross-Presentation of Tumor Antigen by Sharabi, Andrew B, Nirschl, Christopher J, Kochel, Christina M, Nirschl, Thomas R, Francica, Brian J, Velarde, Esteban, Deweese, Theodore L, Drake, Charles G

“…The immune-modulating effects of radiotherapy (XRT) have gained considerable interest recently, and there have been multiple reports of synergy between XRT and…”
Get more information

Magnitude of Therapeutic STING Activation Determines CD8+ T Cell-Mediated Anti-tumor Immunity by Sivick, Kelsey E., Desbien, Anthony L., Glickman, Laura Hix, Reiner, Gabrielle L., Corrales, Leticia, Surh, Natalie H., Hudson, Thomas E., Vu, Uyen T., Francica, Brian J., Banda, Tamara, Katibah, George E., Kanne, David B., Leong, Justin J., Metchette, Ken, Bruml, Jacob R., Ndubaku, Chudi O., McKenna, Jeffrey M., Feng, Yan, Zheng, Lianxing, Bender, Steven L., Cho, Charles Y., Leong, Meredith L., van Elsas, Andrea, Dubensky, Thomas W., McWhirter, Sarah M.

“…Intratumoral (IT) STING activation results in tumor regression in preclinical models, yet factors dictating the balance between innate and adaptive anti-tumor…”
Get full text

Peptide–TLR-7/8a conjugate vaccines chemically programmed for nanoparticle self-assembly enhance CD8 T-cell immunity to tumor antigens by Lynn, Geoffrey M., Sedlik, Christine, Baharom, Faezzah, Zhu, Yaling, Ramirez-Valdez, Ramiro A., Coble, Vincent L., Tobin, Kennedy, Nichols, Sarah R., Itzkowitz, Yaakov, Zaidi, Neeha, Gammon, Joshua M., Blobel, Nicolas J., Denizeau, Jordan, de la Rochere, Philippe, Francica, Brian J., Decker, Brennan, Maciejewski, Mateusz, Cheung, Justin, Yamane, Hidehiro, Smelkinson, Margery G., Francica, Joseph R., Laga, Richard, Bernstock, Joshua D., Seymour, Leonard W., Drake, Charles G., Jewell, Christopher M., Lantz, Olivier, Piaggio, Eliane, Ishizuka, Andrew S., Seder, Robert A.

“…Personalized cancer vaccines targeting patient-specific neoantigens are a promising cancer treatment modality; however, neoantigen physicochemical variability…”
Get full text

Antibody:CD47 ratio regulates macrophage phagocytosis through competitive receptor phosphorylation by Suter, Emily C., Schmid, Eva M., Harris, Andrew R., Voets, Erik, Francica, Brian, Fletcher, Daniel A.

“…Cancer immunotherapies often modulate macrophage effector function by introducing either targeting antibodies that activate Fcγ receptors (FcγRs) or blocking…”
Get full text

Characterization of convergent thickening, a major convergence force producing morphogenic movement in amphibians by Shook, David R, Wen, Jason W H, Rolo, Ana, O'Hanlon, Michael, Francica, Brian, Dobbins, Destiny, Skoglund, Paul, DeSimone, Douglas W, Winklbauer, Rudolf, Keller, Ray E

“…The morphogenic process of convergent thickening (CT) was originally described as the mediolateral convergence and radial thickening of the explanted ventral…”
Get full text

Systemic Tolerance Mediated by Melanoma Brain Tumors Is Reversible by Radiotherapy and Vaccination by Jackson, Christopher M, Kochel, Christina M, Nirschl, Christopher J, Durham, Nicholas M, Ruzevick, Jacob, Alme, Angela, Francica, Brian J, Elias, Jimmy, Daniels, Andrew, Dubensky, Jr, Thomas W, Lauer, Peter, Brockstedt, Dirk G, Baxi, Emily G, Calabresi, Peter A, Taube, Janis M, Pardo, Carlos A, Brem, Henry, Pardoll, Drew M, Lim, Michael, Drake, Charles G

“…Immune responses to antigens originating in the central nervous system (CNS) are generally attenuated, as collateral damage can have devastating consequences…”
Get full text

TNFα and Radioresistant Stromal Cells Are Essential for Therapeutic Efficacy of Cyclic Dinucleotide STING Agonists in Nonimmunogenic Tumors by Francica, Brian J, Ghasemzadeh, Ali, Desbien, Anthony L, Theodros, Debebe, Sivick, Kelsey E, Reiner, Gabrielle L, Hix Glickman, Laura, Marciscano, Ariel E, Sharabi, Andrew B, Leong, Meredith L, McWhirter, Sarah M, Dubensky, Jr, Thomas W, Pardoll, Drew M, Drake, Charles G

“…The cGAS-STING cytosolic DNA sensing pathway may play an integral role in the initiation of antitumor immune responses. Studies evaluating the immunogenicity…”
Get more information

Combining intratumoral Treg depletion with androgen deprivation therapy (ADT): preclinical activity in the Myc-CaP model by Shen, Ying-Chun, Ghasemzadeh, Ali, Kochel, Christina M., Nirschl, Thomas R., Francica, Brian J., Lopez-Bujanda, Zoila A., Carrera Haro, Maria A., Tam, Ada, Anders, Robert A., Selby, Mark J., Korman, Alan J., Drake, Charles G.

“…Background Immune checkpoint blockade has shown promising antitumor activity against a variety of tumor types. However, responses in castration-resistant…”
Get full text

Magnitude of Therapeutic STING Activation Determines CD8+ T Cell-Mediated Anti-tumor Immunity by Sivick, Kelsey E., Desbien, Anthony L., Glickman, Laura Hix, Reiner, Gabrielle L., Corrales, Leticia, Surh, Natalie H., Hudson, Thomas E., Vu, Uyen T., Francica, Brian J., Banda, Tamara, Katibah, George E., Kanne, David B., Leong, Justin J., Metchette, Ken, Bruml, Jacob R., Ndubaku, Chudi O., McKenna, Jeffrey M., Feng, Yan, Zheng, Lianxing, Bender, Steven L., Cho, Charles Y., Leong, Meredith L., van Elsas, Andrea, Dubensky, Thomas W., McWhirter, Sarah M.

Get full text

Dual Blockade of EP2 and EP4 Signaling is Required for Optimal Immune Activation and Antitumor Activity Against Prostaglandin-Expressing Tumors by Francica, Brian J, Holtz, Anja, Lopez, Justine, Freund, David, Chen, Austin, Wang, Dingzhi, Powell, David, Kipper, Franciele, Panigrahy, Dipak, Dubois, Raymond N, Whiting, Chan C, Prasit, Peppi, Dubensky, Thomas W

“…While the role of prostaglandin E2 (PGE2) in promoting malignant progression is well established, how to optimally block the activity of PGE2 signaling remains…”
Get full text

850 Dual blockade of the EP2 and EP4 PGE2 receptors with TPST-1495 is an optimal approach for drugging the prostaglandin pathway by Francica, Brian, Lopez, Justine, Holtz, Anja, Freund, Dave, Wang, Dingzhi, Enstrom, Amanda, Whiting, Sam, Whiting, Chan, Dubensky, Thomas

“…BackgroundProstaglandin E2 (PGE2) is a bioactive lipid produced by tumor cells that drives disease progression through stimulating tumor proliferation,…”
Get full text

Agonist anti-GITR monoclonal antibody and stereotactic radiation induce immune-mediated survival advantage in murine intracranial glioma by Patel, Mira A., Kim, Jennifer E., Theodros, Debebe, Tam, Ada, Velarde, Esteban, Kochel, Christina M., Francica, Brian, Nirschl, Thomas R., Ghasemzadeh, Ali, Mathios, Dimitrios, Harris-Bookman, Sarah, Jackson, Christopher C., Jackson, Christina, Ye, Xiaobu, Tran, Phuoc T., Tyler, Betty, Coric, Vladimir, Selby, Mark, Brem, Henry, Drake, Charles G., Pardoll, Drew M., Lim, Michael

“…BackgroundGlioblastoma (GBM) is a poorly immunogenic neoplasm treated with focused radiation. Immunotherapy has demonstrated synergistic survival effects with…”
Get full text

Erratum to: Agonist anti-GITR monoclonal antibody and stereotactic radiation induce immune-mediated survival advantage in murine intracranial glioma by Patel, Mira A., Kim, Jennifer E., Theodros, Debebe, Tam, Ada, Velarde, Esteban, Kochel, Christina M., Francica, Brian, Nirschl, Thomas R., Ghasemzadeh, Ali, Mathios, Dimitrios, Harris-Bookman, Sarah, Jackson, Christopher C., Jackson, Christina, Ye, Xiaobu, Tran, Phuoc T., Tyler, Betty, Coric, Vladimir, Selby, Mark, Brem, Henry, Drake, Charles G., Pardoll, Drew M., Lim, Michael

“…[This corrects the article DOI: 10.1186/s40425-016-0132-2.]…”
Get full text

Anti-IL-10-mediated Enhancement of Antitumor Efficacy of a Dendritic Cell-targeting MIP3α-gp100 Vaccine in the B16F10 Mouse Melanoma Model Is Dependent on Type I Interferons by Gordy, James T, Luo, Kun, Francica, Brian, Drake, Charles, Markham, Richard B

“…The chemokine MIP3α (CCL20) binds to CCR6 on immature dendritic cells. Vaccines fusing MIP3α to gp100 have been shown to be effective in therapeutically…”
Get full text

A phase 1 study of TPST-1495 as a single agent and in combination with pembrolizumab in subjects with solid tumors by Davar, Diwakar, Powderly, John D., Ulahannan, Susanna Varkey, Johnson, Melissa Lynne, Sharma, Manish, Krauss, John C., Stagg, Robert, Francica, Brian, Moon, Anne, Jenkins, Yonchu, Prasit, Peppi, Dubensky, Thomas Walter, Whiting, Sam H., Papadopoulos, Kyriakos P.

“…TPS2696 Background: Prostaglandin E2 (PGE2) is a bioactive lipid that promotes cancer through diverse mechanisms including stimulating tumor proliferation,…”
Get full text

CLL-1-Targeted Allogeneic CAR-T Cells Exhibit High on-Target Specificity and Potent Cytotoxicity in Preclinical Models of Acute Myeloid Leukemia by Francica, Brian, Garner, Elizabeth, Namburi, Sai, Colgan, Cian, Fowler, Tristan, Mutha, Devin, Aviles, Art, Stanaway, Morena, Guo, Raymond, An, Zili, Kelly, Erin, Degagne, Emilie, Kwong, George, Edwards, Leslie, Jakes, Emma, Shaw, McKay, Schilling, Benjamin, Huynh, Jeremy, Luu, Ricky, Sidorov, Max, Mousali, Rhonda, Otsmaa, Mikk, Lauer, Peter, Skoble, Justin, Kanner, Steven

“…Background: CLL-1 is a compelling therapeutic target for acute myeloid leukemia (AML) as it is highly expressed on AML tumor cells and leukemic stem cells, but…”
Get full text

Paucity of PD-L1 expression in prostate cancer: innate and adaptive immune resistance by Martin, A M, Nirschl, T R, Nirschl, C J, Francica, B J, Kochel, C M, van Bokhoven, A, Meeker, A K, Lucia, M S, Anders, R A, DeMarzo, A M, Drake, C G

“…BACKGROUND: Primary prostate cancers are infiltrated with programmed death-1 (PD-1) expressing CD8+ T-cells. However, in early clinical trials, men with…”
Get full text

Anti-IL-10 mediated enhancement of anti-tumor efficacy of a dendritic-cell targeting MIP3α-gp100 vaccine in the B16F10 mouse melanoma model is dependent on type I interferons by Gordy, James T., Luo, Kun, Francica, Brian, Drake, Charles, Markham, Richard B.

“…The chemokine MIP3α (CCL20) binds to CCR6 on immature dendritic cells. Vaccines fusing MIP3α to gp100 have been shown to be effective in therapeutically…”
Get full text

Abstract 1203: Preclinical development of ADU-1805, a highly selective pan-allele anti-SIRPα antibody that blocks the SIRPα-CD47 innate immune checkpoint by Voets, Erik, Kreijtz, Joost, Vink, Paul, Hulsik, David Lutje, Parade, Mark, Spijkers, Sanne, Reinieren-Beeren, Inge, Rens, Joost, Janssen, Wout, Zandvoort, Peter van, Francica, Brian, Leong, Meredith, Elsas, Andrea van, Eenennaam, Hans van

“…Abstract Background: SIRPα signaling dependent immunoregulatory activity on myeloid cells is activated by binding of its ligand CD47, and blockade of the…”
Get full text